168 related articles for article (PubMed ID: 16870437)
1. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide.
Vlahov IR; Santhapuram HK; Kleindl PJ; Howard SJ; Stanford KM; Leamon CP
Bioorg Med Chem Lett; 2006 Oct; 16(19):5093-6. PubMed ID: 16870437
[TBL] [Abstract][Full Text] [Related]
2. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part II: Folic acid conjugates of tubulysins and their hydrazides.
Vlahov IR; Wang Y; Kleindl PJ; Leamon CP
Bioorg Med Chem Lett; 2008 Aug; 18(16):4558-61. PubMed ID: 18657420
[TBL] [Abstract][Full Text] [Related]
3. Regioselective synthesis of folate receptor-targeted agents derived from epothilone analogs and folic acid.
Vlahov IR; Vite GD; Kleindl PJ; Wang Y; Santhapuram HK; You F; Howard SJ; Kim SH; Lee FF; Leamon CP
Bioorg Med Chem Lett; 2010 Aug; 20(15):4578-81. PubMed ID: 20594844
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate.
Reddy JA; Dorton R; Westrick E; Dawson A; Smith T; Xu LC; Vetzel M; Kleindl P; Vlahov IR; Leamon CP
Cancer Res; 2007 May; 67(9):4434-42. PubMed ID: 17483358
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic.
Leamon CP; Reddy JA; Vlahov IR; Vetzel M; Parker N; Nicoson JS; Xu LC; Westrick E
Bioconjug Chem; 2005; 16(4):803-11. PubMed ID: 16029021
[TBL] [Abstract][Full Text] [Related]
6. Enhanced receptor-mediated endocytosis and cytotoxicity of a folic acid-desacetylvinblastine monohydrazide conjugate in a pemetrexed-resistant cell line lacking folate-specific facilitative carriers but with increased folate receptor expression.
Zhao R; Diop-Bove N; Goldman ID
Mol Pharmacol; 2014 Feb; 85(2):310-21. PubMed ID: 24249723
[TBL] [Abstract][Full Text] [Related]
7. Carbohydrate-based synthetic approach to control toxicity profiles of folate-drug conjugates.
Vlahov IR; Santhapuram HK; You F; Wang Y; Kleindl PJ; Hahn SJ; Vaughn JF; Reno DS; Leamon CP
J Org Chem; 2010 Jun; 75(11):3685-91. PubMed ID: 20423159
[TBL] [Abstract][Full Text] [Related]
8. In vivo structural activity and optimization studies of folate-tubulysin conjugates.
Reddy JA; Dorton R; Dawson A; Vetzel M; Parker N; Nicoson JS; Westrick E; Klein PJ; Wang Y; Vlahov IR; Leamon CP
Mol Pharm; 2009; 6(5):1518-25. PubMed ID: 19630399
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of releasable folate-drug conjugates using a novel heterobifunctional disulfide-containing linker.
Satyam A
Bioorg Med Chem Lett; 2008 Jun; 18(11):3196-9. PubMed ID: 18468892
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of EC140: a novel folate-targeted vinca alkaloid conjugate.
Leamon CP; Reddy JA; Vlahov IR; Kleindl PJ; Vetzel M; Westrick E
Bioconjug Chem; 2006; 17(5):1226-32. PubMed ID: 16984132
[TBL] [Abstract][Full Text] [Related]
11. Design and regioselective synthesis of a new generation of targeted therapeutics. Part 3: Folate conjugates of aminopterin hydrazide for the treatment of inflammation.
Vlahov IR; You F; Santhapuram HK; Wang Y; Vaughn JF; Hahn SJ; Kleindl PJ; Fan M; Leamon CP
Bioorg Med Chem Lett; 2011 Feb; 21(4):1202-5. PubMed ID: 21236665
[TBL] [Abstract][Full Text] [Related]
12. Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145.
Leamon CP; Reddy JA; Vlahov IR; Westrick E; Parker N; Nicoson JS; Vetzel M
Int J Cancer; 2007 Oct; 121(7):1585-92. PubMed ID: 17551919
[TBL] [Abstract][Full Text] [Related]
13. An assembly concept for the consecutive introduction of unsymmetrical disulfide bonds: synthesis of a releasable multidrug conjugate of folic acid.
Vlahov IR; Santhapuram HK; Wang Y; Kleindl PJ; You F; Howard SJ; Westrick E; Reddy JA; Leamon CP
J Org Chem; 2007 Aug; 72(16):5968-72. PubMed ID: 17602528
[TBL] [Abstract][Full Text] [Related]
14. Folate-vinca alkaloid conjugates for cancer therapy: a structure-activity relationship.
Leamon CP; Vlahov IR; Reddy JA; Vetzel M; Santhapuram HK; You F; Bloomfield A; Dorton R; Nelson M; Kleindl P; Vaughn JF; Westrick E
Bioconjug Chem; 2014 Mar; 25(3):560-8. PubMed ID: 24564229
[TBL] [Abstract][Full Text] [Related]
15. Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications.
Leamon CP; Reddy JA; Klein PJ; Vlahov IR; Dorton R; Bloomfield A; Nelson M; Westrick E; Parker N; Bruna K; Vetzel M; Gehrke M; Nicoson JS; Messmann RA; LoRusso PM; Sausville EA
J Pharmacol Exp Ther; 2011 Feb; 336(2):336-43. PubMed ID: 20978169
[TBL] [Abstract][Full Text] [Related]
16. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates.
Reddy JA; Westrick E; Vlahov I; Howard SJ; Santhapuram HK; Leamon CP
Cancer Chemother Pharmacol; 2006 Aug; 58(2):229-36. PubMed ID: 16331500
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationship studies of cytotoxic anhydrovinblastine amide derivatives.
Shao Y; Zhang HK; Ding H; Quan HT; Lou LG; Hu LH
J Nat Prod; 2009 Jun; 72(6):1170-7. PubMed ID: 19499938
[TBL] [Abstract][Full Text] [Related]
18. EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers.
Dosio F; Milla P; Cattel L
Curr Opin Investig Drugs; 2010 Dec; 11(12):1424-33. PubMed ID: 21154124
[TBL] [Abstract][Full Text] [Related]
19. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.
Reddy JA; Westrick E; Santhapuram HK; Howard SJ; Miller ML; Vetzel M; Vlahov I; Chari RV; Goldmacher VS; Leamon CP
Cancer Res; 2007 Jul; 67(13):6376-82. PubMed ID: 17616697
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of a highly-potent and cancer cell selective folate-taxoid conjugate.
Seitz JD; Vineberg JG; Herlihy E; Park B; Melief E; Ojima I
Bioorg Med Chem; 2015 May; 23(9):2187-94. PubMed ID: 25819334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]